M24-742
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer. Nature et Objective:This Phase 1 study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-969 in adult patients with metastatic castration-resistant prostate cancer. The study includes a dose-escalation phase designed to determine […]
PAnTHA
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) Nature and objective :The PAnTHA study aims to assess the safety, tolerance, pharmacokinetics, and preliminary efficacy of 225Ac-PSMA-Trillium, a targeted alpha therapy that is a new class of […]